Denosumab: The era of targeted therapies in bone metastatic diseases

D. Santini, M. E. Fratto, B. Vincenzi, N. Napoli, S. Galluzzo, M. Tantardini, A. Abbruzzese, M. Caraglia, G. Tonini

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This system constituted of the Receptor Activator of nuclear Factor-kB Ligand (RANKL), the Receptor Activator of Nuclear Factor-kB (RANK) and by the decoy Receptor Osteoprotegerin (OPG) plays a central role in bone resorption. Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for RANKL.This review will critically describe and discuss the recent results of clinical trial investigating denosumab in different settings of medical oncology. In particular, we will report the recently published data of clinical trials investigating denosumab in prevention of cancer treatment induced bone loss (CTIBL), in prevention of skeletal related events (SREs) in bone metastatic patients and the ongoing studies in prevention of disease recurrence in the adjuvant setting of solid tumours. The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of bone health care in cancer patients.

Original languageEnglish
Pages (from-to)834-842
Number of pages9
JournalCurrent Cancer Drug Targets
Volume9
Issue number7
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Bone Diseases
Cytoplasmic and Nuclear Receptors
Bone and Bones
Clinical Trials
Ligands
Osteoprotegerin
Neoplasms
Medical Oncology
Therapeutics
Bone Resorption
Monoclonal Antibodies
Delivery of Health Care
Recurrence
Denosumab

Keywords

  • Bone metastases
  • Denosumab
  • Osteoprotegerin
  • Rank
  • Rankl

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Santini, D., Fratto, M. E., Vincenzi, B., Napoli, N., Galluzzo, S., Tantardini, M., ... Tonini, G. (2009). Denosumab: The era of targeted therapies in bone metastatic diseases. Current Cancer Drug Targets, 9(7), 834-842. https://doi.org/10.2174/156800909789760375

Denosumab : The era of targeted therapies in bone metastatic diseases. / Santini, D.; Fratto, M. E.; Vincenzi, B.; Napoli, N.; Galluzzo, S.; Tantardini, M.; Abbruzzese, A.; Caraglia, M.; Tonini, G.

In: Current Cancer Drug Targets, Vol. 9, No. 7, 11.2009, p. 834-842.

Research output: Contribution to journalArticle

Santini, D, Fratto, ME, Vincenzi, B, Napoli, N, Galluzzo, S, Tantardini, M, Abbruzzese, A, Caraglia, M & Tonini, G 2009, 'Denosumab: The era of targeted therapies in bone metastatic diseases', Current Cancer Drug Targets, vol. 9, no. 7, pp. 834-842. https://doi.org/10.2174/156800909789760375
Santini D, Fratto ME, Vincenzi B, Napoli N, Galluzzo S, Tantardini M et al. Denosumab: The era of targeted therapies in bone metastatic diseases. Current Cancer Drug Targets. 2009 Nov;9(7):834-842. https://doi.org/10.2174/156800909789760375
Santini, D. ; Fratto, M. E. ; Vincenzi, B. ; Napoli, N. ; Galluzzo, S. ; Tantardini, M. ; Abbruzzese, A. ; Caraglia, M. ; Tonini, G. / Denosumab : The era of targeted therapies in bone metastatic diseases. In: Current Cancer Drug Targets. 2009 ; Vol. 9, No. 7. pp. 834-842.
@article{892502cab8dd4fc08f01a411779c9f0a,
title = "Denosumab: The era of targeted therapies in bone metastatic diseases",
abstract = "This system constituted of the Receptor Activator of nuclear Factor-kB Ligand (RANKL), the Receptor Activator of Nuclear Factor-kB (RANK) and by the decoy Receptor Osteoprotegerin (OPG) plays a central role in bone resorption. Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for RANKL.This review will critically describe and discuss the recent results of clinical trial investigating denosumab in different settings of medical oncology. In particular, we will report the recently published data of clinical trials investigating denosumab in prevention of cancer treatment induced bone loss (CTIBL), in prevention of skeletal related events (SREs) in bone metastatic patients and the ongoing studies in prevention of disease recurrence in the adjuvant setting of solid tumours. The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of bone health care in cancer patients.",
keywords = "Bone metastases, Denosumab, Osteoprotegerin, Rank, Rankl",
author = "D. Santini and Fratto, {M. E.} and B. Vincenzi and N. Napoli and S. Galluzzo and M. Tantardini and A. Abbruzzese and M. Caraglia and G. Tonini",
year = "2009",
month = "11",
doi = "10.2174/156800909789760375",
language = "English",
volume = "9",
pages = "834--842",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Denosumab

T2 - The era of targeted therapies in bone metastatic diseases

AU - Santini, D.

AU - Fratto, M. E.

AU - Vincenzi, B.

AU - Napoli, N.

AU - Galluzzo, S.

AU - Tantardini, M.

AU - Abbruzzese, A.

AU - Caraglia, M.

AU - Tonini, G.

PY - 2009/11

Y1 - 2009/11

N2 - This system constituted of the Receptor Activator of nuclear Factor-kB Ligand (RANKL), the Receptor Activator of Nuclear Factor-kB (RANK) and by the decoy Receptor Osteoprotegerin (OPG) plays a central role in bone resorption. Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for RANKL.This review will critically describe and discuss the recent results of clinical trial investigating denosumab in different settings of medical oncology. In particular, we will report the recently published data of clinical trials investigating denosumab in prevention of cancer treatment induced bone loss (CTIBL), in prevention of skeletal related events (SREs) in bone metastatic patients and the ongoing studies in prevention of disease recurrence in the adjuvant setting of solid tumours. The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of bone health care in cancer patients.

AB - This system constituted of the Receptor Activator of nuclear Factor-kB Ligand (RANKL), the Receptor Activator of Nuclear Factor-kB (RANK) and by the decoy Receptor Osteoprotegerin (OPG) plays a central role in bone resorption. Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for RANKL.This review will critically describe and discuss the recent results of clinical trial investigating denosumab in different settings of medical oncology. In particular, we will report the recently published data of clinical trials investigating denosumab in prevention of cancer treatment induced bone loss (CTIBL), in prevention of skeletal related events (SREs) in bone metastatic patients and the ongoing studies in prevention of disease recurrence in the adjuvant setting of solid tumours. The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of bone health care in cancer patients.

KW - Bone metastases

KW - Denosumab

KW - Osteoprotegerin

KW - Rank

KW - Rankl

UR - http://www.scopus.com/inward/record.url?scp=72849114497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849114497&partnerID=8YFLogxK

U2 - 10.2174/156800909789760375

DO - 10.2174/156800909789760375

M3 - Article

C2 - 20025571

AN - SCOPUS:72849114497

VL - 9

SP - 834

EP - 842

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 7

ER -